




ISSN 2395-650X

International Journal of
Life Sciences Biotechnology Pharma Sciences

IJLBPS



www.ijlbps.org

E-mail: editorijlbps@gmail.com editor@ijlbps.org

SOLID DISPERSIONS A TECHNOLOGY FOR IMPROVING BIOAVAILABILITY

¹Mrs. M. Sandhya Rani, ²Dr. K. Rajitha, ³Mrs. S. Sabitha

^{1,3}Assistant Professor; ²Professor

^{1,2,3}Department of Pharmaceutics

Vaagdevi Institute of Pharmaceutical Sciences, Bollikunta, Warangal. Telangana.

ABSTRACT

A number of medications that are only weakly water soluble can now be made more bioavailable by using solid dispersions, which have attracted a lot of attention as an efficient way to speed up the dissolution process. These issues have become less common and the dissolution of weakly water-soluble pharmaceuticals has been improved through the use of water-soluble carriers in solid dispersions. Drug dispersion and its stability are crucial to the creation of formulations in solid dispersion, a solubilization technique that focuses primarily on drug-polymer two-component systems. Since a great lot of knowledge has been gained regarding solid dispersion in recent years, this technique is acknowledged as an incredibly helpful way to improve the dissolution characteristics of poorly water-soluble medications; yet, their commercial usefulness is limited. The focus of this review paper is on carriers, BCS classification, and solubility. This page also summarizes some of the most current technological advancements and offers a variety of preparation methods for solid dispersion. The various solid dispersions were highlighted according to their molecular configuration and carrier type. It also provides an overview of the solid dispersion procedures used in the preparation of solid dispersions, their mechanisms, and the medications that are currently on the market.

1. Introduction

The oral route is the most convenience route for drug administration and favours mode of delivery [1]. From the patient's standpoint, swallowing and medication is a comfortable and familiar method of taking medication. As a result, orally delivered drugs are often more effective than alternative modes of administration, such as parenteral, in terms of patient compliance and drug treatment. When an active substance is given orally, it must first dissolve in the stomach and/or intestinal fluids before it can pass through the GI tract's membranes and reach systemic circulation [2]. Therefore, water solubility and/or membrane permeability of the drug molecule are significant contributors to drug absorption from the gastrointestinal (GI) tract, which causes low medication bioavailability of the medications. Consequently, a drug with weak aqueous solubility usually shows a dissolution rate of limited absorption, while a drug with weak membrane permeability usually shows a permeation rate of limited absorption [3].

Pharmaceutical scientists have two approaches to improving the oral bioavailability of pharmacologically active agents: (i) improving the solubility and dissolution rate of poorly water-soluble medications, and (ii) improving the permeability of poorly permeable drugs [4].

In the pharmaceutical literature, a variety of strategies have been used to improve the dissolving capabilities of weakly water-soluble medications other than solid dispersions. Some of these strategies are salt creation, complexation with cyclodextrins, solubilization of pharmaceuticals in solvent(s), and particle size reduction; however, each of these procedures has significant limitations, such as poor yield, expensive, time consuming, and very low drug solubility [5]. On the other hand, formulating pharmaceuticals as solid dispersions provides several processing and excipient alternatives, allowing for greater flexibility for formulating oral delivery systems of poorly tolerated water-soluble medications.

Much of the research that has been published on solid dispersion technologies includes medications that are poorly water-soluble and highly permeable to biological membranes

Table 1: & definitions of various solubility terms [9].

Description forms (solubility definition)	Parts of solvent required for one part of solute	Solubility range (mg/ml)	Solubility assigned (mg/ml)
Very soluble	<1	>1000	1000
Freely soluble (FS)	1 to 10	100-1000	100
Soluble	10-30	33-100	33
Sparingly soluble	30-100	10-33	10
Slightly soluble	100-1000	1-10	1
Very slightly soluble	1000-10000	0.1-1	0.1
Practically insoluble	>10000	<0.1	0.01

as with these drugs dissolution is the rate-limiting step to absorption. As a result, the rate of in vivo absorption will be enhanced in tandem with an increase in the drug dissolution rate. Medications having limited water solubility and strong membrane permeability are classified as class II drugs in the biopharmaceutical classification system (BCS). As a result, solid dispersion technology has many promises to enhance the oral absorption of BCS Class II drugs and their bioavailability [7]

& the weak solubility of many discovered drugs is a barrier to their possible therapeutic activity. According to statistical reports, it has been estimated that 40 per cent of the novel chemical entities identified today are water-insoluble [8]. Unfortunately, many of these prospective medications are abandoned in the early phases of development due to solubility difficulties. As a result, it is becoming increasingly crucial to identify new ways to overcome solubility limits so that the potential therapeutic benefits of these active compounds can be realized [9].

Solid dispersion formulation is one of the most promising and practical approaches for increasing solubility. According to Chiou and Riegelman [3], solid dispersion systems are “the solid-state dispersion of one or more active substances in an inert carrier or matrix generated by the fusion, solvent evaporation, or melting-solvent process.” Matrix is hydrophilic, whereas the medication is hydrophobic. Simple eutectic mixtures, solid solutions, glass solutions, and glass suspensions, amorphous precipitation in a crystalline carrier, compound, or complicated forms are solid dispersion types [3].

2. Solubility

At a particular temperature and pressure, the solubility of a substance is the amount that has entered the solution when an equilibrium is reached between the solution and the excess, that is, an undissolved substance. & the dissolved substance is referred to as the “solute,” and the dissolving fluid in which the solute is dissolved is referred to as the solvent, and the two together are referred to as the solution [10]. Table 1 lists the definitions of various solubility terms.

2.1. Biopharmaceutical Classification System (BCS).

The biopharmaceutical classification system was first devised in 1995 by Amidon and his co-workers [7]. According to the biopharmaceutical classification system, drug substances can be classified as shown in Table 2.

Table 2: Classification of drugs as per the BCS system [7].

Class	Permeability	Solubility
Class I	High	High
Class II	High	Low
Class III	Low	High
Class IV	Low	Low

Bioavailability may be improved by enhancing the solubility and dissolving rate of the class II medication in the gastrointestinal fluids. Medication release is a critical and limiting step for oral drug bioavailability, especially for medicines with limited gastrointestinal solubility. Optimizing the drug release profile of these drugs makes it feasible to improve their bioavailability and reduce side effects [11, 12].

&e World Health Organization's (WHO) model list of essential medicines has assigned a biopharmaceutical classification system categorization based on publicly available data. Unfortunately, only 61 of the 130 orally given medications on the WHO list could be classified with accuracy. Eighty-four percent of these medications are classified as class I, seventeen percent as class II, forty-nine percent as class III, and ten percent as class IV [10].

2.2. Mechanisms Involved in Enhancing Drug Solubilization by Solid Dispersion Technique.

Although the mechanism is not well understood yet, the basic principle includes

the complete removal of drug crystallinity and molecular dispersion of the poorly soluble compound in a hydrophilic polymeric carrier [13]. When the solid dispersion is exposed to the aqueous media, the carrier dissolves and the drug is released as fine colloidal particles. &is increases the surface area of the dissolution rate and hence the bioavailability of poorly water-soluble drugs. &e drug is a soluble hydrophilic carrier and has a better dissolution rate due to the reduction of the particle size and the increase of the particle porosity. &e potential advantage of this technique is enormous. Recently, surfactants were included to improve formulations, as in many cases. However, thermodynamic instability and recrystallization of the drug became a problem. Hence, surfactants are used to avoid recrystallization and to potentiate their solubility [14].

2.3. 5e Justification behind the Use of the Solid Dispersion Technique in the Pharmaceutical Industry.

The primary purposes of using this technique in pharmaceuticals are [15]




Figure 1: Schematic representation of the solid dispersion types [15].

Table 3: Different carriers used in solid dispersion [16].

Category	Carriers
Sugars	Dextrose, sucrose, galactose, sorbitol, maltose, xylitol, mannitol, and lactose
Acids	Citric acid and succinic acid
Polymeric materials	Polyvinyl pyrrolidone (PVP), polyethylene glycol (PEG), hydroxypropyl methylcellulose (HPMC), methylcellulose (MC), hydroxyethyl cellulose, cyclodextrin, hydroxypropyl cellulose, pectin, and galactomannan
Insoluble or enteric polymer	Hydroxy propyl methylcellulose phthalate (HPMCP), Eudragit L100, Eudragit E100, Eudragit RL, Eudragit RS
Surfactants	Polyoxyethylene stearate, poloxamer 188, deoxycholic acid, tweens, and spans
Miscellaneous	Pentaerythritol, pentaerythrityl tetraacetate, urea, urethane, and hydroxy alkyl xanthine

- (i) Enhancing drug solubility
- (ii) Enhancing drug stability
- (iii) Masking the bitter taste of drugs
- (iv) Gaining the desired release profile.

2.4. Types of Solid Dispersions.

Figure 1 summarizes the different types of solid dispersion.

2.5. Based on the Carrier Used.

A carrier must meet the following criteria to be appropriate for enhancing the dissolution rate of a drug. Materials used as carriers are given in Table 3.

- (i) freely water-soluble with intrinsic quick-dissolving capabilities
- (ii) nontoxic and pharmacologically inert
- (iii) &e melting process must be heat stable and it should have a low melting point
- (iv) It must be soluble in a wide range of solvents
- (v) It should be able to preferably increase the aqueous solubility of the drug
- (vi) Ideally, it should be able to boost the medication's water solubility and be chemically compatible with the drug and should not form a firmly bound complex with it [17]

Based on the carrier used, solid dispersions can be classified into the following four generations [18]:

First generation: Solid dispersions were formed as the first carriers to be applied in solid dispersions [19]. In this generation, crystalline carriers are used such as sugars

and urea. &e disadvatange of the first generation is the presence of crystalline nature of the carrier. In which they are thermodynamically stable, and the drug will not be released as fast as the amorphous form [20].

Second generation: &is generation involves the use of amorphous carriers which are usually polymers [21]. &ese polymers could be synthetic such as polyethene




Figure 2: Classifications of solid dispersion [25].

glycols (PEG), povidone, polyvinyl pyrrolidine, and polymethacrylates or natural-based polymers, such as ethyl cellulose, hydroxypropyl methylcellulose (HPMC), and starch derivatives such as cyclodextrins or hydroxypropyl cellulose [22].

&ird generation: It has been proved that the dissolution profile can be enhanced by using a carrier with surface active agent properties. As a result, the use of surface-active agents such as poloxamer 407, compritol 888, ATO, inutec SP1, gelucire 44/14, and inulin as carriers was revealed to be effective in achieving a high purity level of the polymorphic and for increasing in vivo bioavailability [23]. Fourth generation: &is type of dispersion is

described as controlled release solid dispersion. It contains poorly watersoluble drugs with a short biological half-life. &e carriers used are either water-soluble carriers or insoluble water carriers. Solubility enhancement and extended drug release in a controlled manner are the two targets in controlled-release solid dispersion. &e water-soluble carriers used in controlled-release solid dispersion include ethyl cellulose, Eudragit, Hydroxypropyl cellulose, and others [24].

2.6. Based on their Molecular Arrangement.

Solid dispersions can be categorized into the following types (Figure 2):

2.6.1. Eutectics Systems.

This mixture composes of two compounds in the liquid state that are completely miscible but in the solid state only to a very limited extent. It is prepared through fast solidification of the fused melt of the two compounds, giving a complete liquid miscible product and very little solid-solid solubility. Such a system is thermodynamically intimately mixed with the physical mixture of its two crystalline compounds [26].

2.6.2. Glass Solution and Suspensions.

Glass solution refers to the homogeneous glassy system in which a solute is dissolved in a glass carrier, whereas the glass suspensions, in which the precipitated particles are present, are suspended in glass solvent. &e lattice energy in such systems is low, and the melting point is not sharp, examples of carriers that form glass solutions and suspensions are urea, citric acid, polyethylene glycol, polyvinyl pyrrolidone, and sugars such as dextrose, sucrose, and galactose [26].

2.6.3. Solid Solution.

In this system, when the two components crystallize together, they form a single homogeneous phase system. &e drug particle size is decreased to its molecular size in the solid solution. As a result, a faster rate of dissolution will be achieved in the solid solution than in the corresponding eutectic mixture. &e solution can be categorized (as continuous or discontinuous) depending on the level of miscibility of the two compounds or how the solvate molecules are circulated (substitutional, interstitial, or amorphous) [26]




Figure 3: Various methods of solid dispersion preparation [11].

(i) Continuous solid solutions: &e components are miscible in all proportions in a continuous solid solution. Hypothetically, this indicates that the bonding strength between the two components is greater than the bonding strength between the molecules of each individual component. However, solid solutions of this type have not been reported in the pharmaceutical world to date [27].

(ii) Discontinuous solid solutions: In the case of discontinuous solid solutions, the solubility of each component in the other component is limited [27].

(iii) Substitutional solid solutions: &is type of solid solution occurs only if the size of the solute molecules is variable by less than 15% or so from the solvent particles [28].

(iv) Interstitial solid solutions: In interstitial solid solutions, the soluble

particles fill the interstitial gaps between the solvent molecules in the crystal lattice. Therefore, the solute molecule diameter should be less than 0.59 times that of the solvent molecular diameter [28].

3. Method of Preparation

Several techniques for preparing solid dispersion are listed in Figure 3. Generally speaking, there is no best method in solid dispersion to enhance poorly water-soluble drugs. It depends on factors such as the hydrophilicity-hydrophobicity balance of the drug, drug dose, and drug molecular weight. Therefore, trial and error is the best approach to check the proper method that could enhance the drug solubility.

3.1. Fusion.

Sekiguchi and Obi proposed the fusion method in 1961, also known as the melt method. A physical mixture of drug and polymer is heated to generate a molten mixture, which is then cooled and hardened while vigorous stirring is performed. To reach the desired particle size, the solid mass is crushed, pulverized, and sieved. Despite its popularity, several drawbacks to employing this process in making solid dispersions are present. These drawbacks include a lack of drug-polymer miscibility at the heating temperature. However, surfactants may be used to avoid this issue. Additionally, medications and polymers must be thermally stable at melting temperatures, therefore lower production temperatures are desirable. In addition, the fused mixture must be resistant to recrystallization and phase separation [11]. Table 4 shows examples of recent case studies for the preparation of solid dispersion using the fusion method.

3.2. Hot-Melt Extrusion Method.

The hot-melt extrusion method is the modern version of the fusion method in which the extruder induces intense mixing of the components. Compared with the traditional fusion method, melt extrusion offers the potential to shape the molten drug-polymer mixture into implants, pellets, or oral dosage forms [4]. However, this method requires the complete miscibility of the drug and the polymer in the molten state. Solubility parameter phase diagrams can be used to predict miscibility and to rationally select the compatible polymer [11].

This process has various advantages, which includes the following [11]:

- (1) Fewer processing steps because the components are not compressed and the product is not dried, making this procedure simple, continuous, and efficient.
- (2) Entire mixing at a high shear rate and temperature disaggregates the particles, resulting in a uniform distribution of tiny drug particles in the polymer matrix and molecular level dispersion.
- (3) In addition, unlike the classical fusion approach, this technique allows for continuous manufacturing, making it appropriate for large-scale production. HPMC, HPMCAS, PVP, PVP, vinyl acetate, and polyethylene oxide are some of the most often utilized polymeric materials in hot-melt extrusion [4].

Over the last decade, hot-melt extrusion (HME) has developed as an effective technique for drug delivery and has started to host such molecules previously considered unviable as drugs. Hot-melt extrusion is an efficient technology for creating solid molecular dispersions and has been proven to produce sustained, modified, and targeted drug delivery after

improved drug bioavailability [34]. Nonsteroidal antiinflammatory drugs (NSAID) and paracetamol were

Table 4: Shows examples of decent case studies for the preparation of solid dispersion using the fusion method

Drug name	Solubility of the pure drug (mg/L) at 25°C	Solubility of the solid dispersed drug at 25°C	Drug release of the pure drug at 37°C after an hour	Drug release percentage of the solid dispersed drug at 37°C after an hour	Polymer used	Reference
Spironolactone	0.02354	0.06173	27.25	74.24	Polyethylene glycol 4000	[29]
Carvedilol	0.002	0.012	42.6	93.214	Poloxamer 188	[30]
Cefuroxime axetil	0.412	5.886	10	92	Poloxamer 188	[31]
Luteolin	1.93×10^{-3} (at 20°C)	—	13.11	97.78	Polyethylene glycol 4000	[32]
Atorvastatin	<1	—	60	99	Polyethylene glycol 6000	[33]




Figure 4: Schematic presentation coprecipitation process [37].

prepared as orally disintegrating tablets using the hot-melt extrusion method [35]. Paracetamol was prepared using the hot-melt extrusion method through granulation paracetamol and filler excipients with different low molecular weight polyethylene glycol using the hot-melt extrusion process. &e granules achieved were then mixed with disintegrants and lubricant and were compacted into tablets. &e HME granules showed an enhanced drug release profile as compared to the original tablets. More than 80% of the drug was released by tablets that contained 15% of polyethylene glycol within 30 minutes [36], which is the needed amount for paracetamol tablets in the USP 30.

3.3. Coprecipitation Method (Coevaporate).

The carrier is accurately weighed and dissolved in water, while the medication is dissolved in an organic solvent. &e aqueous carrier solution is then added to the organic drug solution after complete dissolution. After that, the solvents are ejected. &e dispersion is crushed, sieved, and dried using a pestle and mortar [37]. Figure 4 shows a demonstration of the process. Table 5 shows examples of decent case studies for the preparation of solid dispersion using the fusion method.

3.4. Solvent Method.

The solvent approach entails dissolving both the medication and the polymer in a single solvent and then removing the solvent to create a solid dispersion. &is method allows for molecule-level mixing, which is favored for improving product solubility and stability [37]. &e fundamental advantage of this approach is that it avoids drug and polymer thermal degradation, which is common when organic solvents are evaporated at low temperatures. When utilizing this strategy, however, formulation scientists face two obstacles [48]. &e first issue is

Table 5: Shows examples of decent case studies for the preparation of solid dispersion using the solvent evaporation method

Drug name	Solubility of the pure drug (mg/L) at 25°C	Solubility of the solid dispersed drug at 25°C	Drug release percentage of the pure drug at 37°C after an hour	Drug release percentage of the solid dispersed drug at 37°C after an hour	Polymer or carrier used	Reference
Nisoldipine	0.005	5	18	75	Polyvinylpyrrolidone	[38]
Nebivolol	0.0403	1.8135	20	98.17	Kleptose HPS, PEG 6000	[39]
Carvedilol	0.002	0.07	7	79	Polyvinylpyrrolidone K 30	[40]
Dutasteride	0.00006	0.0187	60	95.1	PEG 6000	[41]
Cefpodoxime proxetil	0.07211	0.171	20	70	Urea	[42]
Famotidine	0.405	10.436	80 after 35 min	100 after 35 min	Xyloglucan and hyaluronic acid	[43]
Clarithromycin	0.33	—	10	100	Urea	[44]
Ebastine	0.0017	0.014	22	99.68	Avicel® PH101, Avicel® PH 102, croscarmellose sodium(CCS), and sodium starch glycolate (SSG)	[45]
Lovastatin	0.0013	0.00372	30	75	Locust bean gum	[46]
Butein	0.0031	0.114	10 after 24 min	100 after 24	Poloxamer 407 and polyvinyl pyrrolidone K-30	[47]

to combine the medication and the polymer in a single solvent, which can be challenging if the polarity differences are large. Surfactants are sometimes developed to facilitate medication or polymer

solubility in certain solvents. However, their amount in the final dosage form is frequently large, reducing drug loading capacity and potentially causing issues if they are not well tolerated in the body. In addition, this method is expensive due to the necessity to evaporate a substantial amount of the solvent [40]. A second issue is phase separation, which can occur when the solvent is removed. The solution is usually dried by vacuum drying. A rotary evaporator is sometimes used to accomplish rapid drying. The use of higher drying temperatures reduces the time for phase separation. The high molecular mobility of medicine and polymers at high temperatures may speed phase separation [37]. Table 5 shows examples of decent case studies for the preparation of solid dispersion using the solvent evaporation method.

One study was performed with furosemide as it had limited bioavailability, poor solubility, and permeability. The research study intended to assess coprecipitation, kneading, and solvent evaporation by solubility and dissolution enhancement methods. All the approaches were found to enhance the solubility to some extent; however solvent evaporation gave the best results. However, the following order was observed; solvent evaporation > kneading > physical mixtures > coprecipitation [49].

3.5. Spray Drying.

Spray drying has become a prominent processing method for creating solid drug dispersions. It is used to turn a liquid or a suspension into a dry powder in one step. This method allows for more precise control of process factors, resulting in powders with the required size, shape, density, flow characteristics, and crystalline forms [50]. In spray drying, the solvent evaporates at a

rapid rate, resulting in a dramatic increase in viscosity and trapping of drug molecules in the polymer matrix. Drugs with limited water solubility can be spray-dried into extremely fine particles if they are soluble in certain spray-drying solvents. However, the chemical properties of the medication influence the nature of the solid particles generated and spray drying can result in amorphous material, crystalline forms, imperfect crystals, or metastable crystals. Indeed, Mahlin and Bergstrom [51] studied various drug compounds and found that developing an amorphous form is more dependent on the chemical composition of the medications than on process variables. However, the stability of the amorphous forms depends on the process variables. Spray drying provides excellent control over powder characteristics, and it has become the most popular solvent-based production process due to lower manufacturing costs, simplicity of scaleup, and continuous batch production. Table 6 shows a few examples of decent case studies for the preparation of solid dispersion using the spray drying method.

One study used solid dispersion (SD) techniques and modified the locust bean gum (MLBG) as a carrier to enhance lovastatin drug solubility. Solubility and dissolution studies were used, respectively, to examine the effects of polymer concentration and preparation methods on solubility enhancement. According to the solubility study's findings, lovastatin's solubility increased as MLBG concentration increased. It was discovered that the method used for making the solid dispersions affected the dissolution rate of lovastatin. According to dissolution research, among the different ways of preparing solid dispersions, modified solvent evaporation is the most practical

and successful method for improving the solubility of weakly water-soluble lovastatin. &e kneading method improves the dissolution rate better than that of coprecipitation because it has other trituration influences on the drug. Spray drying improves the dissolution rate of lovastatin due to enhanced wettability of drug particles and a significant decrease in particle size in the spray drying procedure. &e explanation for the greater dissolution rate of solvent evaporation in comparison with

Table 6: Shows examples of decent case studies for the preparation of solid dispersion using the spray drying method.

Drug name	Solubility of the pure drug (mg/L) at 25°C	Solubility of the solid dispersed drug at 25°C	Drug release percentage of the pure drug at 37°C after an hour	Drug release percentage of the solid dispersed drug at 37°C after an hour	Polymer or carrier used	Reference
Celecoxib	0.003-0.007	—	59	100	PEG 6000	[52]
Ritonavir	Practically insoluble in water	0.161	8	100	Hydroxypropyl methylcellulose	[53]
Apigenin	0.002	0.016	23	85	Polysamer	[54]

ther solid dispersions could be due to the availability of increased surface area of particles in the suspension [46].

3.6. Supercritical Fluid (SCF) Method.

Supercritical fluids have both liquid and gas characteristics. Materials exhibit liquid-like solvent characteristics and gas-like viscosity, diffusivity, and thermal conductivity under supercritical conditions. While the solvent properties are advantageous for drug/polymer solubilization, the gas-like properties considerably improve the fluids' mass transport characteristics [55]. &is approach is most commonly used with supercritical carbon dioxide (CO₂) as a drug and polymer solvent or as an antisolvent. &e polymer and medicine are dissolved in supercritical CO₂ and blasted into a lowpressure zone through a nozzle, generating adiabatic CO₂ expansion and fast cooling. As a result, this approach enables the creation of drug particles with

much smaller particle sizes. &e rapid expansion of supercritical solutions is the common name for this technology (RESS) [56]. Current supercritical fluid approaches have shown the ability to generate nanoparticulate suspensions of particles with sizes ranging from 5–2000 nm. &is process is considered environmentally friendly because it does not require the use of organic solvents and the small amount of residual CO₂ trapped inside the polymer causes no risk to patients. CO₂'s propensity to plasticize and swell polymers can also be exploited. However, the limited solubility of most medicinal chemicals in CO₂ prevents this method from being used in practice. Several supercritical fluid-processing approaches have been developed to address specific parts of these flaws and to increase solubility. &ese approaches involve precipitation with a compressed antisolvent, supercritical fluidenhanced dispersion, supercritical antisolvent processes, gas antisolvent recrystallization, and an aerosol supercritical extraction system [57]. &e drug solubility in supercritical CO₂ has a huge effect on the diameter ranges of the particles formulated by the RESS process. &is was demonstrated in a study by Kim et al. [58] when they utilized RESS for the formulation of ultrafine drug particles by applying supercritical CO₂, with no organic solvent. &ree different drugs were used (lidocaine, griseofulvin, benzoic acid) with various solubilities in supercritical CO₂, and orifice disks and capillary tubes were fitted as an expansion apparatus. &e drug solubilities in supercritical CO₂ and the impacts of different operating parameters on the physical characteristics of the particles formulated by the RESS procedure were experimentally studied. &e results showed that the average particle diameter

reduced with the solubility for all the drug substances and operating conditions. Response surface methodology was utilized for the optimization of the outcomes, and it was shown that the smallest particle size may be achieved at a temperature of 50°C, a pressure of 17.7 MPa, and a spray distance of 10 cm [59].

3.7. Kneading Method.

In a glass, a mixture of precisely weighed medication and carriers is wetted with a solvent and is thoroughly kneaded for sometime [16]. In the kneading method, the liquid (which may be water or a hydroalcoholic mixture) is added dropwise while the drug and polymers are triturated in a pestle and mortar. &is results in the formation of a slurry and the reduction of particle size, which increases bioavailability because of the kneading action. &en, the mixture is dried and placed through the mesh to bring the contents into homogeneity [60]. Satranidazole-cyclodextrin complexes were made. Following the examination of this complexation, it was discovered that there had been a noticeable increase in solubility [61]. In one study, Olmesartan medoxomil inclusion complexes were created using the kneading approach and were introduced as mouth-dissolving tablets. Complexation increased the solubility and the mechanical stability of the tablets as well as their solubility and dissolution [62]. Efavirenz in PVP K-30 was prepared by two methods, that is, kneading and conventional solvent methods. &e two formulations were characterized by DSC, FT-IR, SEM, XRD, and dissolution profile.

3.8. Electrospinning Method.

This technology combines solid dispersion technology with nanotechnology to be used

in the polymer industry. &is technique exposes a liquid stream of

Table 7: Different characterization methods to assess solid dispersion [6]

Characterization	Technique	Purpose [69]
Drug-carrier interactions	Differential scanning calorimetry (DSC), Fourier transform infrared spectroscopy (FTIR), Raman spectroscopy, and solid-state NMR studies	Used for studying biological reactions and for the validation of production materials and identification of unknown compounds. It is also used for detecting any new interaction
Drug-carrier miscibility	Hot-stage microscopy (HSM), differential scanning calorimeter (DSC), X-ray diffraction (XRD), and nuclear magnetic resonance (NMR)	Used for identifying thermal transition and for achieving a three-dimensional model
Surface properties	Dynamic vapour sorption, inverse gas chromatography, atomic force microscopy, and Raman microscopy	Used for supplying details on particle surface thermodynamic properties, such as surface free energy, acid-base interactions, enthalpy, and entropy. Moreover, it is also used for providing details of the solvent quantity that was absorbed on the sample surface
Physical structures	Scanning electron microscopy, surface area analysis, surface properties, dynamic vapour sorption, inverse gas chromatography, atomic force microscopy, and Raman microscopy	Used for determining the area or pore size of the surfaces sample surface
Stability	Humidity studies, isothermal calorimeter, differential scanning calorimeter (DSC), dynamic vapour sorption, and saturated solubility studies	Used for measuring the reaction between the sample molecules
Amorphous state in solid dispersion	Differential scanning calorimeter (DSC), hot-stage microscopy (HSM), humidity stage microscopy, polarized light optical microscopy, and powder X-ray diffraction	Used for providing a humid environment and for studying the surface properties of the amorphous compounds
Dissolution rate	Dissolution studies, intrinsic dissolution, and dynamic solubility studies	Used for studying the dissolution profile

a drug/polymer solution to a voltage between 5 and 30 kV. Fibres of submicron diameter arise when electrical forces exceed the surface tension of the drug/polymer solution at an air contact [67]. &e generated fibres can be collected on a screen to make a woven fabric, or they can be gathered on a spinning mandrel as the solvent evaporates. Surface tension, dielectric constant, feeding rate, and electric field strength all influence the fibre diameter. Because it is the simplest and cheapest technology for preparing nanofibers and controlling the release of medicines, it has enormous potential. In the future, this approach could be used to make solid dispersions [16]. &e simplicity and low cost of this method make it advantageous. &is technique works well for making nanofibers and managing the release of biomedical treatments. By electrospinning, a nanofiber of polyvinyl alcohol (PVA) : ketoprofen (1 :1, w/w) was created. &e dissolution rate of this nanofiber was significantly greater than that of ketoprofen alone ($p < 0.05$). In a different investigation, indomethacin and

griseofulvin were combined in an amorphous form using the electrospinning technique and the PVP was the carrier. For eight months, this mixture remained stable in a desiccator [68].

4. Solid Dispersion Characterization

In solid dispersions, the medication in the matrix can take on a variety of molecular configurations. &e molecular arrangement in solid dispersions has been studied in several ways. However, much work has gone into distinguishing between amorphous and crystalline materials [16]. For this purpose, many approaches exist to detect the amount of crystalline material in the dispersion. &e amount of amorphous material in a sample can never be directly measured, but it can be estimated based on the amount of

4.1. Marketed Products Used the Solid Dispersion Approach.

Several drugs are already on the market and have been prepared using the various approaches of solid dispersion [12]. Some of the products are shown in Table 8. Different approaches can perform solid dispersion. As a result, solid dispersion methods have been extensively used to improve the solubility of poorly water-soluble drugs. Table 6 shows the Praziquantel drugs that have been studied using different solid dispersion methods with various carriers.

4.2. Solid Dispersion in Polymeric Matrices for In Vitro Studies.

This section covers solid dispersions (SDs) used to improve the characteristics and release of poorly soluble natural and

Table 8: Marketed products [70]

Product name	Drug name	Carrier used	Method used	Company name	Reference
Griseofulv*	Griseofulvin	PEG	Melt process, the exact process is unknown	Pendinal pharm inc.	[71]
Cesamet*	Nabilone	PVP	Process is unknown	Eli Lilly	[71]
Sporanox*	Itraconazole	Hypromellose, HPMC, PEG 20000	Spray layering	Janssen	[71]
Rezulim*	Troglitazone	PVP	Melt-extrusion	Pfizer	[71]
Hepacure*	Hepatitis type b	Amorphous salsolite dipivoxil in solid dispersion	Amorphous salsolite in solid dispersion	CJ Cheiljedang	[22]
Keletra*	Lopinavir	PVP	Melt-extrusion	Abbott	[71]
Aledial*	Nifedipine	Polyoxamer or PVP	Melt/absorb on the carrier	Elan corp, Ireland	[71]
Certican*	Everolimus	HPMC	Melt or spray drying	Novartis, Switzerland	[71]
Fenoglide*	Fenofibrate	PEG	Unknown process	Life cycle pharma, Denmark	[22]
Nivadi*	Nivaldipine	HPM/HPMC	Solvent method	Fujisawa pharmaceuticals co., ltd	[72]
Nimotop*	Nimodipine	PEG	Unknown process	Bayer	[73]
Torcetrapib*	Torcetrapib	HPMC	Unknown process	Pfizer, USA	[71]
Ibuprofen*	Ibuprofen	PEG, HPMC, and PVP	Melt-extrusion	Soliqu, Germany	[71]
Incivik*	Telaprevir	HPMC as	Spray drying	Vertex	[74]
Prograf*	Tacrolimus	HPMC	Wet granulation	Fujisawa pharmaceuticals co., ltd	[74]
Cymbalta*	Duloxetine	HPMC AS	Unknown process	Lilly, USA	[74]
Noxafil*	Posaconazole	HPMC AS	Melt extrusion	Merck	[74]
Intencev*	Etravirine	HPMC	Spray drying	Tibotec, Yardley, PA	[71]
Incivir*	HPMC	HPMC	Spray drying	Janssen pharmaceuticals, Belgium	[74]
Iopitin SRE-240*	Verapamil	Various	Melt-extrusion	Soliqu, Germany	[71]
Iopitin SR-E*	Verapamil	HPM/HPMC HPM/HPMC	Spray drying	Abbott Laboratories, USA,	[75]
Crestor*	Rosuvastatin	HPMC	Solvent evaporation	AstraZeneca	[76]
Zelboraf*	Vemurafenib	HPMC as	Coprecipitation	Roche	[71]
Zortress*	Everolimus	HPMC	Spray drying	Novartis, Switzerland	[74]
Kalymco*	Ivacaftor	HPMC as	New solvent of ivacaftor, processes, exact process unknown	Vertex	[77]

crystalline material present. It should be highlighted that using crystallinity to measure the amount of amorphous drug makes it impossible to distinguish whether the drug is present as amorphous drug particles or as molecularly dispersed molecules. Table 7 summarizes the different methods applied to characterize solid dispersions [6].




Figure 5: Quantification and classification of in vitro studies on solid dispersions published in the period from 2009 to 2020 [78].

synthetic medicines and drug candidates [78]. &e synthesis and usage of SDs have been reported in many in vitro investigations, which have been numerically quantified and categorized in Figure 5 based on the biological activities of

Table 9: In vitro studies on solid dispersion

Drug name	Carrier used	Method used	Activity	Reference
Nicosamide	OHPP	Spray drying	Anticancer	[79]
Pacitaxel	OHPP	Spray drying	Anticancer	[80]
Paclitaxel	PVP/VA TPCS	Spray drying	Anticancer	[81]
Brij®L4	Chrysin	Solvent evaporation	Anticancer	[82]
Curcumin (CM)	Poloxamer 407	Solvent evaporation	Anticancer enzyme inhibitory/ antioxidant anti-inflammatory	[83]
Zn (II)-curcumin complex	PVP K30	Solvent evaporation	Anticancer	[84]
Telaprevir	HPMC, PVP K30, PEG 6000	Kneading	Anticancer	[85]
Angelica gigas nakai	Soluplus®	Hot-melt extruder	Anticancer	[86]
Berberine	Endragit S-100	Solvent evaporation	Anticancer	[87]
hydrochloride (HB)	PVP K30	Scanning electron microscopy	Cytotoxic	[88]
ILIM-290	Poloxamer 407	Solvent evaporation	Antichagasic	[89]
Benzimidazole	Low-substituted HPC	Solvent evaporation	Antichagasic	[90]
Urolic acid	Gelucine 50/13	Solvent evaporation	Antichagasic	[91]
Praziquantel	PVP K30, PVP/VA, kollidon-cl-m, and sodium starch glycolate	Solvent evaporation	Antischistosomal	[92]
Praziquantel	PVP K30	Spray congealing	Antischistosomal	[93]
Artemether	Soluplus, PEG 400, lutoel F127, and lutoel F68	Hot-melt extrudate	Antimalarial	[94]
Lumefantrine	Soluplus, kollidon VA64, and pladone S630	Hot-melt extrudate	Antimalarial	[95]
Abietic acid	Chitosan	Solvent evaporation	Antimicrobial, antioxidant	[96]
Gatifloxacin	Pluronic F127	Solvent evaporation	Antimicrobial	[97]
Curcumin	PVP K30	Coprecipitation	Antimicrobial	[98]
Curcumin	HPMC	Coprecipitation	Antimicrobial	[99]
Curcumin	Poloxamer 407	Coprecipitation	Antioxidant	[100]
Quercetin	PVP K25	Solvent evaporation	Antioxidant	[101]
Coenzyme Q10	Mannitol	Solvent evaporation	Antioxidant	[102]
Uroic acid	PVP K30	Spray drying	Antioxidant	[103]
Luteolin	PEG 4000	Solvent evaporation, fusion, and microwave irradiation	Antioxidant	[104]
α , β -amyrin	PVP K30, PEG 6000, and HPMC	Kneading	Anti-inflammatory	[105]
Curcumin	HPMC	Solvent evaporation	Cytoprotective	[105]

their active compounds, with the major information from this research summarized in Table 9.

4.3. In Vivo Studies on Solid Dispersions in Polymeric Matrices. As previously indicated, solid dispersions (SDs) have been employed in pharmaceutical technology to overcome some of the limits posed by pharmaceuticals and new bioactive substances, such as the limited solubility and bioavailability [78]. In this regard, as seen in Figure 3 and quantitatively quantified in Figure 6, this section discusses in vivo studies on SDs with various biological activities. Table 10 summarizes the most important aspects of this research




Figure 6: Quantification and classification of in vivo studies on solid dispersions published from 2009 to 2020 [78].

Table 10: In vivo studies with solid dispersion.

Drug name	Carrier used	Method used	Activity	Reference
ILIM-290	PVP K30	Solvent evaporation	Anticancer	[88]
9-nitrocamptothecin	Soluplus®	Solvent evaporation	Anticancer	[97]
(-)-olorescandil	(+)-xylitol	Hot melt fusion	Anticancer	[106]
Zinc(II)-curcumin complex	PVP K30	Solvent evaporation	Anticancer	[84]
Selaginella doederleinii hieron	PVP K30	Coprecipitation	Anticancer	[107]
Benzimidazole	Low substituted HPC	Solvent evaporation	Antichagasic	[90]
Curcumin (CM)	PVP K30	Coprecipitation	Antimicrobial	[98]
Taurine-zinc complex	PVP K30	Spray drying	Antioxidant	[108]
Triacetylated andrographolide (TA)	Kollidon (VA64)	Solvent evaporation	Anti-inflammatory	[109]
Curcumin	PVP K30, poloxamer 188	Solvent evaporation	Anti-inflammatory	[110]
Acetofenac	Croscopolone	Solvent evaporation	Anti-inflammatory	[111]
Curcumin	Gelucine®50/13-aerosol®	Hot melt fusion	Anti-inflammatory	[112]
Curcumin	HPMC, lactic acid and isomalt	Hot melt extrusion	Anti-inflammatory	[113]
Ibuprofen	PEG 8000	Fusion method	Anti-inflammatory	[114]
Flurbiprofen	Urea and mannitol	Fusion method	Anti-inflammatory	[115]
Meloxicam	Paracetamol	Coprecipitation	Anti-inflammatory	[116]
Cheylethrine (CHE)	PVP K30	Solvent evaporation	Anti-inflammatory	[117]
Curcumin	HPMC	Solvent evaporation	Hepatoprotective	[105]
Nobiletin	HPMC	Spray drying	Hepatoprotective	[118]
Silymarin	PVP K30	Solvent evaporation	Hepatoprotective	[119]
Repaglinide	Poloxamer 188	Fusion method	Antihyperglycemic	[120]
Glimepiride	Soluplus1 and PEG 4000	Solvent evaporation	Antidiabetic	[121]
Pioglitazone	PVP K17	Spray drying	Antihyperglycemic	[122]
Hexogenin acetate	HPMC	Kneading	Antinociceptive	[63]

5. Drawbacks of Solid Dispersions

There are several drawbacks that limit the use of solid dispersion in the drug formulation process, including [18] the following:

- Demanding and costly techniques of preparation
- Physicochemical properties reproducibility
- Difficulty merging dosage forms into the formulation
- Scaling up of the manufacturing process
- Stability of medications and solvent

6. Conclusion

Due to its ease of use and convenience, oral medication administration is the most popular and recommended method of delivery. As far as the patient is concerned, taking medication orally is a convenient and habitual method. Because of this, oral medication delivery often outperforms alternative routes of administration, such as parenteral, in terms of patient compliance and drug therapy. Before an active medication taken orally may pass through the GI tract's membranes and enter the bloodstream, it must dissolve in the stomach and/or intestinal fluids.

Therefore, low drug absorption from the gastrointestinal (GI) tract, which is greatly impacted by the drug's molecule's water solubility and membrane permeability, is the reason of low medication

bioavailability. It has been shown that using solid dispersion systems can improve the way that pharmaceuticals that aren't very soluble in water dissolve more readily. Although solid dispersion technology has been better understood recently, there is still little application for it in real life.

Recently, a number of strategies have been tried to get over obstacles and improve the preparation's realism. Additionally, as different solutions have been developed, the problems associated with combining dosage forms into formulation have become increasingly overcome. Two instances are filling capsules directly and spraying sugar beads. The purpose and objectives of this study have been covered. A review design was used to carry out this research investigation. There were several significant restrictions on the study. There is no explicit methodology section in this research study where the design is explained and supported. This article has also not discussed the methods used to get the data or the quantity of articles chosen for the data collection. Future studies on this topic should overcome these limitations.

The drug release profile of poorly water-soluble medications can be significantly improved by solid dispersion technology, despite the fact that there are still many obstacles to overcome, such as scale-up and production costs.

Data Availability

It is a review of articles with no hyperlinks are applicable.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Advances in Pharmacological and Pharmaceutical Sciences

References

- [1] K. Dhirendra, S. Lewis, N. Udupa, and K. Atin, "Solid dispersions: a review," *Pakistan Journal of Pharmaceutical Sciences*, vol. 22, no. 2, pp. 234–246, 2009.
- [2] A. Alagga and V. Gupta, "Drug absorption," *xPharm: 5e Comprehensive Pharmacology Reference*, Elsevier Inc, Amsterdam, Netherlands, 2021.
- [3] W. L. Chiou and S. Riegelman, "Pharmaceutical applications of solid dispersion systems," *Journal of Pharmaceutical Sciences*, vol. 60, no. 9, pp. 1281–1302, 1971.
- [4] J. M. Vasoya, H. H. Desai, S. G. Gumaste et al., "Development of solid dispersion by hot melt extrusion using mixtures of polyoxylglycerides with polymers as carriers for increasing dissolution rate of a poorly soluble drug model," *Journal of Pharmaceutical Sciences*, vol. 108, no. 2, pp. 888–896, 2019.
- [5] K. T. Savjani, A. K. Gajjar, and J. K. Savjani, "Drug solubility: importance and enhancement techniques," *ISRN Pharmaceuticals*, vol. 2012, Article ID 195727, 10 pages, 2012.
- [6] P. Greeshmika, S. Kavya, S. Sayeeda, B. Hemalatha, and K. Padmalatha, "Solid dispersion: strategy to enhance solubility," *Indo-American Journal of Pharmaceutical Sciences*, vol. 8, pp. 1812–1823, 2021.
- [7] G. L. Amidon, H. Lennernäs, V. P. Shah, and J. R. Crison, "A theoretical basis for a biopharmaceutic drug classification:

the correlation of in vitro drug product dissolution and in vivo bioavailability,” *Pharmaceutical Research*, vol. 12, no. 3, pp. 413–420, 1995.

[8] S. Kalepu and V. Nekkanti, “Insoluble drug delivery strategies: review of recent advances and business prospects,” *Acta Pharmaceutica Sinica B*, vol. 5, no. 5, pp. 442–453, 2015.

[9] R. Ravichandran, “Nanoparticles in drug delivery: potential green nanomedicine applications,” *International Journal of Green Nanotechnology: Biomedicine*, vol. 1, 2009.

[10] S. Verma, I. Kumar, and A. Chaudhary, “Solid dispersion: different methods of enhancing solubility and classification of solid dispersion,” *International Journal of Advance Research, Ideas and Innovations in Technology*, vol. 5, pp. 65–71, 2019.

[11] S. Baghel, H. Cathcart, and N. J. O’Reilly, “Polymeric amorphous solid dispersions: a review of amorphization, crystallization, stabilization, solid-state characterization, and aqueous solubilization of biopharmaceutical classification system class II drugs,” *Journal of Pharmaceutical Sciences*, vol. 105, no. 9, pp. 2527–2544, 2016.

[12] A. Dharna, N. Singh, and A. Sandeep, “Solid dispersions: a review on drug delivery system and solubility enhancement| international journal of pharmaceutical sciences and research,” *International Journal of Pharmaceutical Sciences and Research*, vol. 4, 2013.

[13] S. Sareen, L. Joseph, and G. Mathew, “Improvement in solubility of poor water-soluble drugs by solid dispersion,”

International Journal of Pharmaceutical Investigation, vol. 2, no. 1, p. 12, 2012.

[14] N. M. Patro, A. Sultana, K. Terao et al., “Comparison and correlation of in vitro, in vivo and in silico evaluations of alpha, beta and gamma cyclodextrin complexes of curcumin,” *Journal of Inclusion Phenomena and Macrocyclic Chemistry*, vol. 78, no. 1-4, pp. 471–483, 2014.

[15] S. P. Kumar, R. Malviya, and P. K. Sharma, “Cancer pain: a critical review of mechanism-based classification and physical therapy management in palliative care,” *Indian Journal of Palliative Care*, vol. 17, no. 2, pp. 116–126, 2011.

[16] K. Poddar, “Solid dispersions: an approach towards enhancing dissolution rate,” *International Journal of Pharmacy and Pharmaceutical Sciences*, vol. 3, pp. 9–19, 2011.

[17] K. Dixit, P. Singh, and S. Stuti, “Solid dispersion-a strategy for improving the solubility of poorly soluble drugs,” *International Journal of Research in Pharmaceutical and Biomedical Sciences*, vol. 3, pp. 90–964, 2012.

[18] K. Bhawana, K. Ramandeep, K. Sukhdeep, K. Sukhkaran, and B. Himani, “Solid dispersion: an evolutionary approach for solubility enhancement of poorly water soluble drugs,” *International Journal of Recent Advances in Pharmaceutical Research*, vol. 2, pp. 1–6, 2012.

[19] M. Salah Attia, A. Ali Hasan, F. E. S. Ghazy, E. Gomaa, and M. Attia, “Solid dispersion as a technical solution to boost the dissolution rate and bioavailability of poorly water-soluble drugs,” *Indian Journal*

of Pharmaceutical Education and Research,
vol. 55, pp. s327–s339, 2021.

[20] Z. Zhang, W. Li, G. Wang, Y. L. Qu,
and D. G. Yu, “Electrospun 4th-generation
solid dispersions of poorly watersoluble
drug utilizing two different processes,”
Journal of Nanomaterials, vol. 2018, Article
ID 2012140, 10 pages, 2018.